Our finding that CpG ± GM administration in melanoma patients enforces antitumor immunity through DC activation, a skewed Th1 response, and the boosting of CD8+ cytotoxic T cell responses is in keeping with previous observations in animal studies [14, 37]. The gene discussed is CD8A; the disease is melanoma.